# Atopic Dermatitis FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/atopic-dermatitis

> 20 upcoming FDA catalysts in atopic Dermatitis: RINVOQ® (upadacitinib, ABBV) on January 2027 (primary completion); RINVOQ® (upadacitinib, ABBV) on Jan to Apr 2027 (topline data readout); lutikizumab (ABBV) on May 2027 (primary completion); lutikizumab (ABBV) on May to Aug 2027 (topline data readout); and 16 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May 21, 2025 | [Ruxolitinib cream primary completion](https://sec-api.dev/pdufa/ruxolitinib-cream) | INCY | Atopic Dermatitis | completed | "NCT06238817 (A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-21 (ACTUAL); Lead Sponsor Incyte Corporation; Results First Posted 2026-05-22." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06238817)) |
| July 31, 2025 | [Rocatinlimab primary completion](https://sec-api.dev/pdufa/rocatinlimab) | AMGN | Atopic Dermatitis | completed | "NCT05633355 (A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-31 (ACTUAL); Lead Sponsor Amgen; Results First Posted 2026-07-24." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05633355)) |
| September 25, 2025 | [Lebrikizumab primary completion](https://sec-api.dev/pdufa/lebrikizumab) | LLY | Atopic Dermatitis | completed | "NCT06280716 (A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-25 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-10-16." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06280716)) |
| October 23, 2025 | [Sar444656 (kt-474) primary completion](https://sec-api.dev/pdufa/sar444656-kt-474) | SNY | Atopic Dermatitis | withdrawn | "NCT06058156 (Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-10-23 (ACTUAL); Lead Sponsor Sanofi; Results First Posted 2026-11-03." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06058156)) |
| Mar 2026 | [Soquelitinib trial start](https://sec-api.dev/pdufa/soquelitinib) | CRVS | atopic dermatitis | completed | "In March 2026, we initiated a Phase 2 clinical trial of soquelitinib for the treatment of atopic dermatitis." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1626971/000110465926123317/crvs-20260930x10q.htm)) |
| May 6, 2026 | [Barzolvolimab primary completion](https://sec-api.dev/pdufa/barzolvolimab) | CLDX | Atopic Dermatitis | completed | "NCT06727552 (A Study of Barzolvolimab in Patients With Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-05-06 (ACTUAL); Lead Sponsor Celldex Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06727552)) |
| May 22, 2026 | [Ruxolitinib cream topline data readout](https://sec-api.dev/pdufa/ruxolitinib-cream) | INCY | Atopic Dermatitis | completed | "NCT06238817 (A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-21 (ACTUAL); Lead Sponsor Incyte Corporation; Results First Posted 2026-05-22." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06238817?tab=results)) |
| 2H 2026 | [ATI-052 topline data readout](https://sec-api.dev/pdufa/ati-052) | ACRS | atopic dermatitis | scheduled | "Dosing is ongoing in both trials, and top line results from both are expected in the second half of 2026. (press releases here and here)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1557746/000110465926056669/acrs-20260507xex99d1.htm)) |
| July 1, 2026 | [Rocatinlimab primary completion](https://sec-api.dev/pdufa/rocatinlimab) | AMGN | Atopic Dermatitis | withdrawn | "NCT05882877 (A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2026-07-01 (ACTUAL); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05882877)) |
| July 23, 2026 | [Evo756, dose 1 primary completion](https://sec-api.dev/pdufa/evo756) | EVMN | Atopic Dermatitis | completed | "NCT07150845 (Phase 2b Study of EVO756 in Adults With Atopic Dermatitis): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-07-23 (ACTUAL); Lead Sponsor Evommune, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07150845)) |
| July 24, 2026 | [Rocatinlimab topline data readout](https://sec-api.dev/pdufa/rocatinlimab) | AMGN | Atopic Dermatitis | completed | "NCT05633355 (A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-31 (ACTUAL); Lead Sponsor Amgen; Results First Posted 2026-07-24." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05633355?tab=results)) |
| August 7, 2026 | [JAKAFI (ruxolitinib) primary completion](https://sec-api.dev/pdufa/ruxolitinib) | INCY | Atopic Dermatitis | completed | "NCT06832618 (A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-07 (ACTUAL); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06832618)) |
| October 9, 2026 | [Dupixent (dupilumab) primary completion](https://sec-api.dev/pdufa/dupilumab) | REGN | Atopic Dermatitis | completed | "NCT02612454 (Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-10-09 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02612454)) |
| Oct 2026 to Jan 2027 | [Dupixent (dupilumab) topline data readout](https://sec-api.dev/pdufa/dupilumab) | REGN | Atopic Dermatitis | scheduled | "NCT02612454 (Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-10-09 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02612454)) |
| October 16, 2026 | [Lebrikizumab topline data readout](https://sec-api.dev/pdufa/lebrikizumab) | LLY | Atopic Dermatitis | completed | "NCT06280716 (A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-25 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-10-16." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06280716?tab=results)) |
| Nov 2026 to Feb 2027 | [Pf-07275315 dose 1 topline data readout](https://sec-api.dev/pdufa/pf-07275315) | PFE | Atopic Dermatitis | scheduled | "NCT05995964 (A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-12 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05995964)) |
| November 2026 | [RINVOQ® (upadacitinib) primary completion](https://sec-api.dev/pdufa/upadacitinib) | ABBV | Atopic Dermatitis | scheduled | "NCT06389136 (A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06389136)) |
| Nov 2026 to Feb 2027 | [RINVOQ® (upadacitinib) topline data readout](https://sec-api.dev/pdufa/upadacitinib) | ABBV | Atopic Dermatitis | scheduled | "NCT06389136 (A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06389136)) |
| November 2026 | [Pf-07275315 dose 1 primary completion](https://sec-api.dev/pdufa/pf-07275315) | PFE | Atopic Dermatitis | scheduled | "NCT05995964 (A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-12 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05995964)) |
| January 2027 | [RINVOQ® (upadacitinib) primary completion](https://sec-api.dev/pdufa/upadacitinib) | ABBV | Atopic Dermatitis | scheduled | "NCT06701331 (Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06701331)) |
| Jan to Apr 2027 | [RINVOQ® (upadacitinib) topline data readout](https://sec-api.dev/pdufa/upadacitinib) | ABBV | Atopic Dermatitis | scheduled | "NCT06701331 (Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06701331)) |
| May 2027 | [Lutikizumab primary completion](https://sec-api.dev/pdufa/lutikizumab) | ABBV | Atopic Dermatitis | scheduled | "NCT06718101 (A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-05 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06718101)) |
| May to Aug 2027 | [Lutikizumab topline data readout](https://sec-api.dev/pdufa/lutikizumab) | ABBV | Atopic Dermatitis | scheduled | "NCT06718101 (A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-05 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06718101)) |
| May to Aug 2027 | [GIA632 topline data readout](https://sec-api.dev/pdufa/gia632) | NVS | Atopic Dermatitis | scheduled | "NCT07220577 (Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-05-17 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07220577)) |
| May 2027 | [GIA632 primary completion](https://sec-api.dev/pdufa/gia632) | NVS | Atopic Dermatitis | scheduled | "NCT07220577 (Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-05-17 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07220577)) |
| June 2027 | [KT-621 primary completion](https://sec-api.dev/pdufa/kt-621) | KYMR | Atopic Dermatitis | scheduled | "NCT07217015 (A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Kymera Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07217015)) |
| Jun to Sep 2027 | [KT-621 topline data readout](https://sec-api.dev/pdufa/kt-621) | KYMR | Atopic Dermatitis | scheduled | "NCT07217015 (A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Kymera Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07217015)) |
| August 2027 | [Tapinarof cream, 1% primary completion](https://sec-api.dev/pdufa/tapinarof-cream-1) | OGN | Atopic Dermatitis | scheduled | "NCT07265479 (A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Organon and Co." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07265479)) |
| Aug to Nov 2027 | [Tapinarof cream, 1% topline data readout](https://sec-api.dev/pdufa/tapinarof-cream-1) | OGN | Atopic Dermatitis | scheduled | "NCT07265479 (A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Organon and Co." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07265479)) |
| Mar to Jun 2028 | [Tilrekimig topline data readout](https://sec-api.dev/pdufa/tilrekimig) | PFE | Atopic Dermatitis | scheduled | "NCT07765888 (A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-10 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07765888)) |
| March 2028 | [Tilrekimig primary completion](https://sec-api.dev/pdufa/tilrekimig) | PFE | Atopic Dermatitis | scheduled | "NCT07765888 (A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-10 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07765888)) |
| Sep to Dec 2028 | [Tilrekimig topline data readout](https://sec-api.dev/pdufa/tilrekimig) | PFE | Atopic Dermatitis | scheduled | "NCT07783425 (A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-08 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07783425)) |
| September 2028 | [Tilrekimig primary completion](https://sec-api.dev/pdufa/tilrekimig) | PFE | Atopic Dermatitis | scheduled | "NCT07783425 (A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-08 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07783425)) |
| Nov 2028 to Feb 2029 | [GHZ339 topline data readout](https://sec-api.dev/pdufa/ghz339) | NVS | Atopic Dermatitis | scheduled | "NCT06947993 (Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-11-27 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06947993)) |
| November 2028 | [GHZ339 primary completion](https://sec-api.dev/pdufa/ghz339) | NVS | Atopic Dermatitis | scheduled | "NCT06947993 (Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-11-27 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06947993)) |
| Apr to Jul 2029 | [Cibinqo (abrocitinib) topline data readout](https://sec-api.dev/pdufa/abrocitinib) | PFE | Atopic Dermatitis | scheduled | "NCT07823595 (Abrocitinib Treatment of Atopic Dermatitis in Children 2 to Less Than 6 Years of Age): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2029-04-10 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07823595)) |
| April 2029 | [Cibinqo (abrocitinib) primary completion](https://sec-api.dev/pdufa/abrocitinib) | PFE | Atopic Dermatitis | scheduled | "NCT07823595 (Abrocitinib Treatment of Atopic Dermatitis in Children 2 to Less Than 6 Years of Age): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2029-04-10 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07823595)) |
| November 2029 | [RINVOQ® (upadacitinib) primary completion](https://sec-api.dev/pdufa/upadacitinib) | ABBV | Atopic Dermatitis | scheduled | "NCT06461897 (A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-11 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06461897)) |
| Nov 2029 to Feb 2030 | [RINVOQ® (upadacitinib) topline data readout](https://sec-api.dev/pdufa/upadacitinib) | ABBV | Atopic Dermatitis | scheduled | "NCT06461897 (A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-11 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06461897)) |

## Drugs

- [Ruxolitinib cream](https://sec-api.dev/pdufa/ruxolitinib-cream) (INCY)
- [Rocatinlimab](https://sec-api.dev/pdufa/rocatinlimab) (AMGN)
- [Lebrikizumab](https://sec-api.dev/pdufa/lebrikizumab) (LLY)
- [Sar444656 (kt-474)](https://sec-api.dev/pdufa/sar444656-kt-474) (SNY)
- [Soquelitinib](https://sec-api.dev/pdufa/soquelitinib) (CRVS)
- [Barzolvolimab](https://sec-api.dev/pdufa/barzolvolimab) (CLDX)
- [ATI-052](https://sec-api.dev/pdufa/ati-052) (ACRS)
- [Evo756, dose 1](https://sec-api.dev/pdufa/evo756) (EVMN)
- [JAKAFI (ruxolitinib)](https://sec-api.dev/pdufa/ruxolitinib) (INCY)
- [Dupixent (dupilumab)](https://sec-api.dev/pdufa/dupilumab) (REGN)
- [Pf-07275315 dose 1](https://sec-api.dev/pdufa/pf-07275315) (PFE)
- [RINVOQ® (upadacitinib)](https://sec-api.dev/pdufa/upadacitinib) (ABBV)
- [Lutikizumab](https://sec-api.dev/pdufa/lutikizumab) (ABBV)
- [GIA632](https://sec-api.dev/pdufa/gia632) (NVS)
- [KT-621](https://sec-api.dev/pdufa/kt-621) (KYMR)
- [Tapinarof cream, 1%](https://sec-api.dev/pdufa/tapinarof-cream-1) (OGN)
- [Tilrekimig](https://sec-api.dev/pdufa/tilrekimig) (PFE)
- [GHZ339](https://sec-api.dev/pdufa/ghz339) (NVS)
- [Cibinqo (abrocitinib)](https://sec-api.dev/pdufa/abrocitinib) (PFE)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/atopic-dermatitis.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Atopic Dermatitis FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/atopic-dermatitis

```bibtex
@misc{secapidev_indications_atopic_dermatitis_20261116,
  title        = {Atopic Dermatitis FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/atopic-dermatitis}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_atopic_dermatitis_20261116","title":"Atopic Dermatitis FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/atopic-dermatitis","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
